Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Theranexus    ALTHX   FR0013286259

THERANEXUS

(ALTHX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Historically, the company has been releasing figures that are above expectations.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The stock is in a well-established, long-term rising trend above the technical support level at 7.46 EUR
Weaknesses
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • The company has insufficient levels of profitability.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
THERANEXUS497.04%81
-
GILEAD SCIENCES, INC.-5.94%76 616
VERTEX PHARMACEUTICALS5.18%59 887
REGENERON PHARMACEUTICALS36.91%54 257
WUXI APPTEC CO., LTD.64.21%39 976
BIONTECH SE236.51%27 452
GENMAB A/S58.76%24 885
BEIGENE, LTD.48.70%22 473
ARGENX SE66.85%13 673
HUALAN BIOLOGICAL ENGINEERI..62.18%12 281
MYOKARDIA, INC.208.58%11 993
-
MIRATI THERAPEUTICS, INC.81.87%11 784
SAREPTA THERAPEUTICS, INC.13.10%11 517
ASCENDIS PHARMA A/S21.20%9 007
NEUROCRINE BIOSCIENCES, INC..-11.68%8 860
ULTRAGENYX PHARMACEUTICAL I..174.83%7 765
More Results
Financials
Sales 2020 25,4 M 30,7 M 30,7 M
Net income 2020 20,1 M 24,3 M 24,3 M
Net cash 2020 58,0 M 70,3 M 70,3 M
P/E ratio 2020 3,51x
Yield 2020 -
Capitalization 71,8 M 86,8 M 87,0 M
EV / Sales 2020 0,55x
EV / Sales 2021 2,04x
Nbr of Employees 17
Free-Float 57,4%
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating -
Investor Rating -
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability -
P/E ratio
Potential
Yield -
Consensus -
7 days EPS revision
4 months EPS revision
1 year EPS revision -
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes